vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused...
Pharmaceutical
Xequel Bio Expands Leadership Team with Appointments of Dr. Michael J. Brubaker as Chief Scientific Officer and Tony C. Tipton as Chief Operating Officer
Seasoned Biopharma Executives Bring Significant Clinical Development and Commercial Expertise Michael Brubaker, Ph.D., Xequel Bio, Chief Scientific Officer “The addition...
Biora Therapeutics to Participate in Upcoming BTIG Investment Conference
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutics,...
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development Arm
Julia Kirshner, Ph.D. Predictive Oncology Appoints Julia Kirshner, Ph.D., as Chief Scientific OfficerEAGAN, Minn., July 26, 2022 (GLOBE NEWSWIRE) --...
KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting
CELEBRATION, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused...
TRACON Pharmaceuticals Announces Dosing of 36th Patient in ENVASARC Pivotal Trial Triggering Initial IDMC Efficacy Review Expected in the Fourth Quarter
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a...
Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022
The Company Will Host a Conference Call and Webcast on August 10, 2022, at 8:30 AM ETCORAL GABLES, Fla., July...
ORYZON Collaborates with the CMT Research Foundation in the US
To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth diseaseCMTRF to provide funding for in vivo efficacy tests in CMT preclinical modelMADRID...
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH
MoonLake Immunotherapeutics signs development and manufacturing agreement with Vetter Pharma International GmbH ZUG, Switzerland, July 26, 2022 – MoonLake Immunotherapeutics...
AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility
— FDA feedback marks a key milestone in the construction of the facility expected to support AGTC’s pipeline, including the...
Aquestive Therapeutics to Participate in Wedbush PacGrow Healthcare Conference
WARREN, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve...
Rubius Therapeutics to Announce Second Quarter 2022 Financial Results
CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is biologically...
Paladin Phase 4 Study Confirms Safety of Durable ILUVIEN® Treatment and Reduces Burden of Care For DME Patients
Data from the recent 0.19 mg FAc implant Phase 4 observational real-world study were presented at the annual American Society...
CinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
Open Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected...
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
SOD1-ALS is a rare genetic form of ALS that affects approximately 330 people in the U.S.,1 it is progressive, leads...
Inozyme Pharma Secures Flexible Debt Facility for up to $70 Million with K2 HealthVentures
BOSTON, July 26, 2022 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel...
Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting
JERUSALEM, July 26, 2022 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the...
BridgeBio Pharma Announces Positive Interim Results from a Phase 2 Trial of Infigratinib in Achondroplasia Demonstrating an Increase in Annualized Height Velocity of 1.52 cm/year in Children 5 Years of Age and Older, and Adds 5th Cohort to Trial
- At the highest dose level evaluated to date (Cohort 4, 0.128 mg/kg once daily), the mean change from baseline...
Rapid Therapeutic Science Laboratories File S1 and completes Mid-Year Strategy Review
DALLAS, July 26, 2022 (GLOBE NEWSWIRE) -- Rapid Therapeutics Science Laboratories (OTC: RTSL) ("Rapid Therapeutic'' or the "Company"), a growth-oriented...
Reneo Pharmaceuticals Reports Positive Results from REN001 Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD) Study and Provides Additional Development Updates
LC-FAOD program to move forward into the next stage of clinical developmentEnrollment of pivotal STRIDE study in primary mitochondrial myopathies...